Mereo BioPharma Group (MREO)
Mereo BioPharma Statistics
Share Statistics
Mereo BioPharma has 30.95M shares outstanding. The number of shares has increased by 10.48% in one year.
| Shares Outstanding | 30.95M |
| Shares Change (YoY) | 10.48% |
| Shares Change (QoQ) | -10.6% |
| Owned by Institutions (%) | 68.65% |
| Shares Floating | 28.46M |
| Failed to Deliver (FTD) Shares | 1.34K |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 7.2M, so 4.65% of the outstanding shares have been sold short.
| Short Interest | 7.2M |
| Short % of Shares Out | 4.65% |
| Short % of Float | 5.07% |
| Short Ratio (days to cover) | 5.49 |
Valuation Ratios
The PE ratio is -10.34 and the forward PE ratio is -129.45. Mereo BioPharma's PEG ratio is 0.28.
| PE Ratio | -10.34 |
| Forward PE | -129.45 |
| PS Ratio | 30.47 |
| Forward PS | 0.7 |
| PB Ratio | 6.03 |
| P/FCF Ratio | -14.14 |
| PEG Ratio | 0.28 |
Enterprise Valuation
Mereo BioPharma Group has an Enterprise Value (EV) of 1,523.3B.
| EV / Earnings | -51696.43 |
| EV / Sales | 152328.71 |
| EV / EBITDA | -58462.05 |
| EV / EBIT | -53606.67 |
| EV / FCF | -70682.9 |
Financial Position
The company has a current ratio of 6.72, with a Debt / Equity ratio of 0.12.
| Current Ratio | 6.72 |
| Quick Ratio | 6.72 |
| Debt / Equity | 0.12 |
| Total Debt / Capitalization | 10.54 |
| Cash Flow / Debt | -3.55 |
| Interest Coverage | -9.86 |
Financial Efficiency
Return on equity (ROE) is -0.58% and return on capital (ROIC) is -49.41%.
| Return on Equity (ROE) | -0.58% |
| Return on Assets (ROA) | -0.44% |
| Return on Capital (ROIC) | -49.41% |
| Revenue Per Employee | 303.03K |
| Profits Per Employee | -892.91K |
| Employee Count | 33 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -532K |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
The stock price has increased by -38.54% in the last 52 weeks. The beta is 0.85, so Mereo BioPharma's price volatility has been higher than the market average.
| Beta | 0.85 |
| 52-Week Price Change | -38.54% |
| 50-Day Moving Average | 3.13 |
| 200-Day Moving Average | 3.74 |
| Relative Strength Index (RSI) | 23.7 |
| Average Volume (20 Days) | 1.12M |
Income Statement
In the last 12 months, Mereo BioPharma had revenue of 10M and earned -29.47M in profits. Earnings per share was -220.04.
| Revenue | 10M |
| Gross Profit | 7.43M |
| Operating Income | -28.42M |
| Net Income | -29.47M |
| EBITDA | -26.06M |
| EBIT | -28.42M |
| Earnings Per Share (EPS) | -220.04 |
Balance Sheet
The company has 57.42M in cash and 5.95M in debt, giving a net cash position of 51.47M.
| Cash & Cash Equivalents | 57.42M |
| Total Debt | 5.95M |
| Net Cash | 51.47M |
| Retained Earnings | -419.63M |
| Total Assets | 88.75M |
| Working Capital | 72.52M |
Cash Flow
In the last 12 months, operating cash flow was -21.13M and capital expenditures -419K, giving a free cash flow of -21.55M.
| Operating Cash Flow | -21.13M |
| Capital Expenditures | -419K |
| Free Cash Flow | -21.55M |
| FCF Per Share | -0.03 |
Margins
Gross margin is 74.26%, with operating and profit margins of -284.16% and -294.66%.
| Gross Margin | 74.26% |
| Operating Margin | -284.16% |
| Pretax Margin | -299.98% |
| Profit Margin | -294.66% |
| EBITDA Margin | -260.56% |
| EBIT Margin | -284.16% |
| FCF Margin | -215.51% |
Dividends & Yields
MREO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -9018.03% |
| FCF Yield | -28.48% |
Analyst Forecast
The average price target for MREO is $7, which is 186.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 186.9% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 6.3 |
| Piotroski F-Score | 2 |